Nano and microparticle drug delivery systems for the treatment of Brucella infections.


Journal

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295

Informations de publication

Date de publication:
31 Dec 2023
Historique:
received: 05 04 2023
revised: 06 11 2023
accepted: 07 11 2023
medline: 7 12 2023
pubmed: 19 11 2023
entrez: 18 11 2023
Statut: ppublish

Résumé

Nano-based drug delivery systems are increasingly used for diagnosis, prevention and treatment of several diseases, thanks to several beneficial properties, including the ability to target specific cells or organs, allowing to reduce treatment costs and side effects frequently associated with chemotherapeutic medications, thereby improving treatment compliance of patients. In the field of communicable diseases, especially those caused by intracellular bacteria, the delivery of antibiotics targeting specific cells is of critical importance to maximize their treatment efficacy. Brucella melitensis, an intracellular obligate bacterium surviving and replicating inside macrophages is hard to be eradicated, mainly because of the low ability of antibiotics to enter these phagocityc cells . Although different antibiotics regimens including gentamicin, doxycycline and rifampicin are in fact used against the Brucellosis, no efficient treatment has been attained yet, due to the intracellular life of the respective pathogen. Nano-medicines responding to environmental stimuli allow to maximize drug delivery targeting macropages, thereby boosting treatment efficacy. Several drug delivery nano-technologies, including solid lipid nanoparticles, liposomes, chitosan, niosomes, and their combinations with chitosan sodium alginate can be employed in combination of antibiotics to successfully eradicate Brucellosis infection from patients.

Identifiants

pubmed: 37979375
pii: S0753-3322(23)01673-6
doi: 10.1016/j.biopha.2023.115875
pii:
doi:

Substances chimiques

Chitosan 9012-76-4
Anti-Bacterial Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

115875

Informations de copyright

Copyright © 2023. Published by Elsevier Masson SAS.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Ali Razei (A)

Chemical Injuries Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran. Electronic address: ali.razei@gmail.com.

Mohammad Javanbakht (M)

Nephrology and Urology Research Center,Clinical Science Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran. Electronic address: mhmjvbt81@gmail.com.

Abbas Hajizade (A)

Biology Research Centre, Faculty of Basic Sciences, Imam Hossain University, Tehran, Iran.

Mohammad Heiat (M)

Baqiyatallah Research Center for Gastroenterology and Liver Diseases (BRCGL), Clinical Sciences Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.

Shi Zhao (S)

JC School of Public Health and Primary Care, Chinese University of Hong Kong, Hong Kong, China.

Hossien Aghamollaei (H)

Chemical Injuries Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.

Mojtaba Saadati (M)

Biology Research Centre, Faculty of Basic Sciences, Imam Hossain University, Tehran, Iran.

Mostafa Khafaei (M)

Human Genetics Research Center, Baqiyatallah Medical Science University, Tehran, Iran.

Mosa Asadi (M)

Nephrology and Urology Research Center,Clinical Science Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.

Luca Cegolon (L)

University of Trieste, Department of Medical, Surgical & Health Sciences, Trieste, Italy; University Health Agency Giuliano-Isontina (ASUGI), Public Health Department, Trieste, Italy.

Amir Homayoun Keihan (AH)

Molecular Biology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH